Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064221 | 0.82 | KDM4E (0.44) | L3MBTL1KDM4EALDH1A1LMNACA12 | |
| SCHEMBL15587576 | 0.81 | PAX8 (0.37) | L3MBTL1KDM4EMCHR1ALDH1A1HTT | |
| SCHEMBL15545096 | 0.81 | KDM4E (0.39) | L3MBTL1KDM4EALDH1A1HTTCA12 | |
| SCHEMBL18753138 | 0.79 | MCHR1 (0.46) | L3MBTL1KDM4EMCHR1ALDH1A1HTT | |
| SCHEMBL4073525 | 0.76 | KDM4E (0.36) | L3MBTL1KDM4EALDH1A1HTTCA12 | |
| SCHEMBL15544883 | 0.75 | GABRP (0.39) | L3MBTL1KDM4EMCHR1GABRPGABRD | |
| SCHEMBL15544895 | 0.70 | ALDH1A1 (0.41) | L3MBTL1KDM4EALDH1A1HTTLMNA | |
| SCHEMBL18147051 | 0.69 | ALDH1A1 (0.51) | L3MBTL1KDM4EALDH1A1HTTLMNA | |
| SCHEMBL17467128 | 0.68 | GABRP (0.39) | L3MBTL1KDM4EMCHR1GABRPGABRD | |
| SCHEMBL17442650 | 0.68 | GABRP (0.53) | KDM4EGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | L3MBTL1 3339/4885KDM4E 1025/4885MCHR1 12/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | L3MBTL1 3339/4885KDM4E 1025/4885MCHR1 12/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | L3MBTL1 3339/4885KDM4E 1025/4885MCHR1 12/4885 |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | L3MBTL1 3339/4885KDM4E 1025/4885MCHR1 12/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | L3MBTL1 3339/4885KDM4E 1025/4885MCHR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.